ReviewAntibiotics (Basel, Switzerland)2022
Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Current and future options for the treatment of serious infections due to carbapenem-resistantClinical microbiology reviews · 2025Review
- In Vitro Activity of Cefiderocol Against Multi-Drug-Resistant Gram-Negative Clinical Isolates in Romania.Antibiotics (Basel, Switzerland) · 2025Article
- Review
- Impact of urbanization on antimicrobial resistance in soil microbial communities.Scientific reports · 2025Article
- Review
- Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence.Life (Basel, Switzerland) · 2024Review
- Sepsis Stewardship: The Puzzle of Antibiotic Therapy in the Context of Individualization of Decision Making.Journal of personalized medicine · 2024Review
- An Overview of Cefiderocol's Therapeutic Potential and Underlying Resistance Mechanisms.Life (Basel, Switzerland) · 2023Review
- Characterization ofAntibiotics (Basel, Switzerland) · 2023Article
- Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Review
- Novel Antimicrobial Agents for Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2023Review
- What to Do with the New Antibiotics?Antibiotics (Basel, Switzerland) · 2023Review
- Infective Endocarditis Associated with Implantable Cardiac Device by Metallo-β-Lactamase-Producing Pseudomonas aeruginosa, Successfully Treated with Source Control and Cefiderocol Plus Imipenem.Antimicrobial agents and chemotherapy · 2023Article
- Real-world experience with cefiderocol therapy forAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Next-Generation Sequencing of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Cefiderocol Is an Effective Topical Monotherapy for Experimental Extensively Drug-ResistantOphthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: healthcare-associated infections are one of the most frequent adverse events in healthcare delivery worldwide. Several antibiotic resistance mechanisms have been developed, including those to carbapenemase. Cefiderocol (CFD) is a novel siderophore cephalosporin designed to treat carbapenem-resistant bacteria. (2) Methods: we performed a systematic review of all cases reported in the literature to outline the existing evidence. We evaluated real-world evidence studies of CFD in the treatment of carbapenem-resistant (CR) bacteria. (3) Results: a total of 19 publications treating cases of infection by CR bacteria were included. The three most frequent CR pathogens were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.